Literature DB >> 32353745

The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome.

Satoshi Gando1, Seitaro Fujishima2, Daizoh Saitoh3, Atsushi Shiraishi4, Kazuma Yamakawa5, Shigeki Kushimoto6, Hiroshi Ogura7, Toshikazu Abe8, Toshihiko Mayumi9, Junichi Sasaki10, Joji Kotani11, Naoshi Takeyama12, Ryosuke Tsuruta13, Kiyotsugu Takuma14, Norio Yamashita15, Shin-Ichiro Shiraishi16, Hiroto Ikeda17, Yasukazu Shiino18, Takehiko Tarui19, Taka-Aki Nakada20, Toru Hifumi21, Yasuhiro Otomo22, Kohji Okamoto23, Yuichiro Sakamoto24, Akiyoshi Hagiwara25, Tomohiko Masuno26, Masashi Ueyama27, Satoshi Fujimi5, Yutaka Umemura7.   

Abstract

BACKGROUND: Multiple organ dysfunction syndrome (MODS) is a predominant cause of death in acute respiratory distress syndrome (ARDS). Disseminated intravascular coagulation (DIC) is recognized as a syndrome that frequently develops MODS. To test the hypothesis that DIC scores are useful for predicting MODS development and that DIC is associated with MODS, we retrospectively analyzed the data of a prospective, multicenter study on ARDS.
METHODS: Patients who met the Berlin definition of ARDS were included. DIC scores as well as the disease severity and the development of MODS on the day of the diagnosis of ARDS (day 0) and day 3 were evaluated. The primary and secondary outcomes were the development of MODS and the hospital mortality.
RESULTS: In the 129 eligible patients, the prevalence of DIC was 45.7% (59/129). DIC patients were more seriously ill and exhibited a higher prevalence of MODS on days 0 and 3 than non-DIC patients. The DIC scores on day 0 detected the development of MODS with good area under the receiver operating characteristic curve (0.714, p<.001). DIC on day 0 was significantly associated with MODS on days 0 and 3 (odds ratio 1.53 and 1.34, respectively). Patients with persistent DIC from days 0 to 3 had higher rates of both MODS on day 3 (p=.035) and hospital mortality (p=.031) than the other patients.
CONCLUSIONS: DIC scores were able to predict MODS, and DIC was associated with MODS during the early stage of ARDS. Persistent DIC may also have role in this association.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute respiratory distress syndrome (ARDS); Disseminated intravascular coagulation (DIC); Mortality; Organ dysfunction

Mesh:

Year:  2020        PMID: 32353745     DOI: 10.1016/j.thromres.2020.03.023

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

Review 1.  Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression.

Authors:  Günther Schönrich; Martin J Raftery; Yvonne Samstag
Journal:  Adv Biol Regul       Date:  2020-07-04

Review 2.  COVID-19 update: Covid-19-associated coagulopathy.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

Review 3.  Recent advances in the research and management of sepsis-associated DIC.

Authors:  Toshiaki Iba; Jean Marie Connors; Isao Nagaoka; Jerrold H Levy
Journal:  Int J Hematol       Date:  2021-01-02       Impact factor: 2.490

4.  Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC).

Authors:  Colin Pawlowski; Tyler Wagner; Arjun Puranik; Karthik Murugadoss; Liam Loscalzo; A J Venkatakrishnan; Rajiv K Pruthi; Damon E Houghton; John C O'Horo; William G Morice; Amy W Williams; Gregory J Gores; John Halamka; Andrew D Badley; Elliot S Barnathan; Hideo Makimura; Najat Khan; Venky Soundararajan
Journal:  Elife       Date:  2020-08-17       Impact factor: 8.140

Review 5.  Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus.

Authors:  Upendra K Katneni; Aikaterini Alexaki; Ryan C Hunt; Tal Schiller; Michael DiCuccio; Paul W Buehler; Juan C Ibla; Chava Kimchi-Sarfaty
Journal:  Thromb Haemost       Date:  2020-08-24       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.